Clinical Trial Update: Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose dobutamine and a single-dose tocilizumab in patients with acute myocardial infarction at high risk of cardiogenic shock; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiogenic Shock
• Myocardial Infarction

Drugs mentioned

• Dobutamine (dobutamine)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Acute Myocardial Infarction, Cardiogenic Shock | Phase 2 | Status: ACTIVE_NOT_RECRUITING